trial · primary record
Petosemtamab
Colorectal Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 600 |
| Primary completion | 2030-01-31 |
| Primary endpoint | Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT07775287 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:38.893Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07775287
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Petosemtamab · compound